The Weekly Roundup: Rules of Attraction (4.26.19)

April 27, 2019 | Pamela Youngberg

“Often staying successful is about learning and changing rather than sticking to the tried-and-true.” —Dane Holmes, Head of Human Capital Management, Goldman Sachs

This week, AARP and McDonald’s announced a program to help fill a quarter of a million seasonal jobs and a pilot program designed to match low-income seniors with jobs. When Goldman Sachs faced a recruiting crisis, it took two key steps to make sure it was reaching the best talent available: It widened the funnel to capture a broader range of applicants and identified the key competencies required to succeed at the firm, then stuck to structured questions to get at those competencies.

Continue reading →

The Weekly Roundup: Insulin May Be the Canary in the Coal Mine (4.19.19)

April 19, 2019 | Pamela Youngberg

A subcommittee of the House Energy and Commerce Committee heard testimony earlier this month on the human toll of rising insulin costs as a case study to better understand the impact on patients on prescription pricing overall. According to Rep. Brett Guthrie (R-KY 2nd District), “The prescription drug supply chain is complex, and it lacks transparency. There is limited public information around drug prices due to a lack of transparency around rebates and other price concessions.” The Kaiser Family Foundation recently reported that total Medicare Part D spending on insulin increased by 840% between 2007 and 2017, with no generics available and Eli Lilly, Novo Nordisk, and Sanofi dominating the market. In Minnesota, Attorney General Lori Swanson sued the three. While common wisdom (and massive advertising dollars spent by the Big Pharma lobby) justify high prices as attributable to the cost of R&D, rising insulin costs—which have been averaging 10 percent annually—may go a long way toward putting that argument to bed.

Continue reading →

}